RP
Insider
RA Capital Nexus Fund III, L.P.
DirectorRA Capital Nexus Fund III, L.P. (Director) filed 2 Form 4 reports as a reporting entity in the past 24 months (1 purchase, 1 sale), most often in Mineralys Therapeutics, Inc. (MLYS). Across 1 priced purchase filing, the average 21-session return was -6.4% from execution and -2.5% from disclosure (delay-adjusted; derived). The largest single filing was $17.5M of MLYS (1,296,296 sh × $13.50, as filed), executed Mar 13 2025. Data as of Nov 8 2026.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
-6.4%
avg across 1 priced filings
Delay-adjustediThe same average, entered at disclosure dates
-2.5%
same 1 filings, from disclosure
Filings, ttm
2
1 buys · 1 sells
Median delay
4d
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$32.3M
shares × price, as filed
Last traded
Oct 28 2025
Filed Oct 28 2025
Median ADV $10.0M across their filed names
Open performance→Volume by month
Buys $17.5M
Sells $14.8M
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
2 filings
Sector per market data · by filing · past 24 months
Most traded names
MLYS
Mineralys Therapeutics, Inc.
MLYS · 1 buy · 0 sells
1 filing
SIONRecent filings
SIONSALE
Sionna Therapeutics, Inc.
View filing →
$14.8M373,610 sh across 8 lots
Exec Oct 24 2025
Filed Oct 28 2025 · 5:30 PM ET MLYSPURCHASE Mineralys Therapeutics, Inc. View filing → $17.5M
1,296,296 sh × $13.50
Exec Mar 13 2025
Filed Mar 17 2025 · 5:30 PM ET